Wakefulness Test News Today

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.

Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

BOSTON and LONDON, April 22, 2024 -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today...

Centessa has received FDA clearance to start a phase 1 trial of ORX750, aimed at narcolepsy and other sleep-wake disorders.

Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b,…

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Takeda announced results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.